Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19
Virulence, Volume 13, No. 1, Year 2022
Notification
URL copied to clipboard!
Description
Antibodies to SARS-CoV-2 are central to recovery and immunity from COVID-19. However, the relationship between disease severity and the repertoire of antibodies against specific SARS-CoV-2 epitopes an individual develops following exposure remains incompletely understood. Here, we studied seroprevalence of antibodies to specific SARS-CoV-2 and other betacoronavirus antigens in a well-annotated, community sample of convalescent and never-infected individuals obtained in August 2020. One hundred and twenty-four participants were classified into five groups: previously exposed but without evidence of infection, having no known exposure or evidence of infection, seroconverted without symptoms, previously diagnosed with symptomatic COVID-19, and recovered after hospitalization with COVID-19. Prevalence of IgGs specific to the following antigens was compared between the five groups: recombinant SARS-CoV-2 and betacoronavirus spike and nucleocapsid protein domains, peptides from a tiled array of 22-mers corresponding to the entire spike and nucleocapsid proteins, and peptides corresponding to predicted immunogenic regions from other proteins of SARS-CoV-2. Antibody abundance generally correlated positively with severity of prior illness. A number of specific immunogenic peptides and some that may be associated with milder illness or protection from symptomatic infection were identified. No convincing association was observed between antibodies to Receptor Binding Domain(s) (RBDs) of less pathogenic betacoronaviruses HKU1 or OC43 and COVID-19 severity. However, apparent cross-reaction with SARS-CoV RBD was evident and some predominantly asymptomatic individuals had antibodies to both MERS-CoV and SARS-CoV RBDs. Findings from this pilot study may inform development of diagnostics, vaccines, and therapeutic antibodies, and provide insight into viral pathogenic mechanisms. © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Authors & Co-Authors
Gregory, David J.
United States, Boston
Massachusetts General Hospital
United States, Boston
Harvard Medical School
Pavlovic, Maia N.
United States, Boston
Massachusetts General Hospital
Chronos, Nicolas A.F.
Unknown Affiliation
Charles, Richelle C.
United States, Boston
Harvard Medical School
United States, Boston
Massachusetts General Hospital
United States, Boston
Harvard T.h. Chan School of Public Health
Ryan, Edward Thomas
United States, Boston
Massachusetts General Hospital
United States, Boston
Harvard T.h. Chan School of Public Health
LaRocque, Regina C.
United States, Boston
Harvard Medical School
United States, Boston
Massachusetts General Hospital
Miller, Tyler E.
United States, Boston
Harvard Medical School
United States, Boston
Massachusetts General Hospital
García-Beltrán, Wilfredo F.
United States, Boston
Harvard Medical School
United States, Boston
Massachusetts General Hospital
Thierauf, Julia Cara
United States, Boston
Harvard Medical School
United States, Boston
Massachusetts General Hospital
Iafrate, Anthony John
United States, Boston
Harvard Medical School
United States, Boston
Massachusetts General Hospital
Naranbhai, Vivek
United States, Boston
Harvard Medical School
United States, Boston
Massachusetts General Hospital
Poznansky, Mark C.
United States, Boston
Massachusetts General Hospital
United States, Boston
Harvard Medical School
Statistics
Citations: 6
Authors: 12
Affiliations: 4
Identifiers
Doi:
10.1080/21505594.2022.2073025
ISSN:
21505594
Research Areas
Covid
Study Design
Cross Sectional Study